Prescription drug · NDA
Amvuttra (vutrisiran) NDC 71336-1003
Vutrisiran sodium 25 mg/.5mL · Injection · Subcutaneous · Alnylam Pharmaceuticals, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 71336-1003-1 | 71336100301 | 1 SYRINGE, GLASS in 1 CARTON (71336-1003-1) / .5 mL in 1 SYRINGE, GLASSMarketed from Jun 13, 2022 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Amvuttra
- Generic name (nonproprietary)
- vutrisiran
- Active ingredients
- Vutrisiran sodium — 25 mg/.5mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 215515
- Marketing start
- Listing expires
- Other FDA classes
- Decreased RNA Integrity (Physiologic effect)Increased Protein Breakdown (Physiologic effect)Small Interfering (Chemical structure)
- Identifiers
- Product ID 71336-1003_1791a81a-d261-4b66-b699-273afe02c380SPL ID 1791a81a-d261-4b66-b699-273afe02c380SPL set ID 8db0facb-81b6-4006-9239-27dc6409c5d3RxCUI 2604788, 2604794UNII 28O0WP6Z1P
- Pharmacologic class
- Small Interfering RNA; Transthyretin-directed RNA Interaction
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N471336100301followed by a unit qualifier and the quantityPackage 71336-1003-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 ) 1.1 Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. 1.2 Cardiomyopathy of Wild-type or Hereditary Transthyretin-mediated Amyloidosis AMVUTTRA is indicated for the treatment of…
Excerpt only. Read the full label for complete information.